Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib + cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
NL-OMON50375Phase 2Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Pierre Fabre Laboratories. Primary endpoint: Confirmed overall response rate by local assessment. Started Dec 2019; status: active, not recruiting.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON50375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50375.